Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, Sarici F, Kertmen N, Esin E, Akin S, Ates O, Aksoy S, Sever AR, Altundag K.
Babacan T, et al. Among authors: altundag k.
Tumori. 2015 Jul-Aug;101(4):418-23. doi: 10.5301/tj.5000332.
Tumori. 2015.
PMID: 25953439
Clinical Trial.